Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program

Stock Information for Bolt Biotherapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Bolt Biotherapeutics Inc.

Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy
Prothena Reports Second Quarter 2025 Financial Results and Business Highlights
Prothena to Report Second Quarter 2025 Financial Results on August 4
Prothena Announces Corporate Restructuring
Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease
Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint
Prothena Reports First Quarter 2025 Financial Results and Business Highlights

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.